RankAlpha logo
Back to Rankings

IMDX

Insight Molecular DiagnosticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
View Chart
Current thesis
A first-mover FDA authorization for a kitted dd-cfDNA transplant assay could shift IMDX from development story to commercial platform, with February financing reducing immediate balance-sheet stress and management highlighting growing transplant-center engagement [#10-K-2026-03-26] [#PR-2026-03-26].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.6.
What can break
Cash runway improved after the February 2026 raise, but losses remain heavy and future financing risk is not eliminated.
Momentum
97
Value
41
Sentiment
6
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.20 · Bull $5.80 · Bear $2.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $8.33
Why
Momentum97 · Δ7d +1.6
Value41 · Δ7d +0.0
Sentiment6 · Δ7d +5.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendFlat
Δ7d
+1.6
Δ21d
+17.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
6
33% active weight
Current posture
7d trendImproving
Δ7d
+5.5
Δ21d
-6.0
Why this grade

Composite grade C. Momentum 96.7 / Value 41.1 / Sentiment 6.1

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$192.13M
Beta
1.35
Shares Out
28.66M
P/E (TTM) · Derived
-1.4
P/S (TTM)
48.64
P/FCF (TTM) · Derived
-7.50
Rev YoY
+126.1%
EPS YoY
+65.6%
Gross Margin
+54.7%
Op Margin
-1392.9%
Net Debt
-$7.7M
Current Ratio
2.79
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology